EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study

Tomiki Sumiyoshi iD, Yasunori Morio, Takahiro Kawashima, Hisateru Tachimori, Seiji Hongo, Taishiro Kishimoto iD, Koichiro Watanabe, Tempei Otsubo, Hideki Oi, Kazuyuki Nakagome iD, Jun Ishigooka

Neuropsychopharmacology Reports · 2024

DOI: 10.1002/npr2.12411 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Tomiki Sumiyoshi und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Center of Neurology and Psychiatry, Tokyo, Japan. Hauptthemen laut MEDLINE: Major Depressive Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sumitomo Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Interview quality is an important factor in the success of clinical trials for major depressive disorder (MDD). There is a substantial need to establish a reliable, remote clinical assessment interview system that can replace traditional in‐person interviews.

Methods

We conducted a multicenter, randomized, unblinded, prospective, cross‐sectional study to assess the reliability of remote interviews in patients with MDD (UMIN000041839). Eligible patients with MDD underwent remote and in‐person sessions of the Montgomery‐Åsberg Depression Rating Scale (MADRS) assessment performed by different raters within 28 days of providing consent. Patients were randomized to a group first assessed using in‐person interviews and secondarily using remote interviews (in‐person‐first group) or a group first assessed by remote interviews and secondarily using in‐person interviews (remote‐first group). Nineteen trained people (15 clinical psychologists, 3 nurses, and 1 clinical laboratory technologist) performed interviews.

Results

Of 59 patients (in‐person‐first group, n = 32; remote‐first group, n = 27) who completed both remote and in‐person interviews, 51% ( n = 30) were women; the mean age was 41.6 years (range, 21–64 years). There was a strong association between remote and in‐person MADRS scores ( r = 0.891, kappa = 0.901). An overall intraclass correlation coefficient (ICC) of 0.886 (95% confidence interval, 0.877–0.952) indicated good consistency between MADRS scores in remote and in‐person interviews. The ICC decreased as the severity of depression increased.

Conclusion

Our results suggest remote interviews are a feasible alternative option to in‐person interviews in assessing symptom severity in MDD patients and could promote clinical trials in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderAdultCross-Sectional StudiesPatient AcuityReproducibility of ResultsFemaleHumansMiddle AgedMaleYoung AdultFeasibility StudiesProspective StudiesPilot ProjectsEast Asian People

Stichwörter der Autor:innen

major depressive disordermobile applicationspilot projectpsychiatric status rating scalepsychological interviews

Autor:innen und Institutionen

  • National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Ichigaya Himorogi Clinic, Tokyo, Japan.
  • Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan.
  • Psychiatry Department, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
  • Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan.
  • Department of Psychosomatic & Psychiatric Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.

ORCID-Profile: Tomiki Sumiyoshi, Taishiro Kishimoto, Kazuyuki Nakagome

Förderung

  • Sumitomo Pharma Co., Ltd.
  • Meiji Seika Pharma Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Janssen Pharmaceutical K.K.
  • Otsuka Pharmaceutical
  • Takeda Pharmaceutical Company

Zitieren

APA

Sumiyoshi, T., Morio, Y., Kawashima, T., Tachimori, H., Hongo, S., Kishimoto, T., Watanabe, K., Otsubo, T., Oi, H., Nakagome, K., & Ishigooka, J. (2024). Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12411

Vancouver

Sumiyoshi T, Morio Y, Kawashima T, Tachimori H, Hongo S, Kishimoto T, et al. Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12411

BibTeX
@article{Sumiyoshi2024,
  author = {Sumiyoshi, Tomiki and Morio, Yasunori and Kawashima, Takahiro and Tachimori, Hisateru and Hongo, Seiji and Kishimoto, Taishiro and Watanabe, Koichiro and Otsubo, Tempei and Oi, Hideki and Nakagome, Kazuyuki and Ishigooka, Jun},
  title = {Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study},
  journal = {Neuropsychopharmacology Reports},
  year = {2024},
  doi = {10.1002/npr2.12411}
}
Kostenlos starten →